Forbion is a leading European life sciences venture capital firm investing in innovative biotech companies across human health and planetary health. The firm manages approximately €5 billion across multiple fund strategies, spanning formation, ventures, and growth stages, with offices in Naarden, Munich, and Boston.
54% of their portfolio is in Biotech & Life Sciences. Deal activity increased 39% year-over-year (25 deals in the last 12 months). Average disclosed round size is $103.7M (across 131 rounds with reported amounts).
Portfolio
132
Fund Size
—
Top Stage
Series A
Last 12 Mo
25
Team
Geert-Jan Mulder MD
Managing Partner
Martien van Osch MSc
Managing Partner & CFO
Sander Slootweg MSc
Managing Partner
Marco Boorsma PhD
General Partner
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Tropic | Series C | $105M | Dec 2026 |
 OMass Therapeutics | Series C | $310M | Oct 2026 |
 Braveheart Bio | Unknown | $185M | Sep 2026 |
 Aiolos | Series A | $245M | Sep 2026 |
| PPrecirix | Series B | — | Aug 2026 |
 Kynexis | Series A | — | Aug 2026 |
 RQ Biotechnology | Series A | $115M | Jun 2026 |
 cAMPfield Therapeutics | Series A | $180M | Jun 2026 |
| CcAMPfield | Series A | $180M | Jun 2026 |
 Solstice | Series A | $21M | May 2026 |
 CellCentric | Series D | $220M | May 2026 |
 Coultreon Biopharma | Series A | $125M | Apr 2026 |
 Coultreon Biopharma | Series A | $125M | Apr 2026 |
 Mestag Therapeutics Limited | Series B | $40M | Mar 2026 |
 Tropic | Series C | $105M | Mar 2026 |
| Tropic | Series C | $105M | Mar 2026 |
 Tropic Biosciences | Bridge | $105M | Mar 2026 |
 Slate Medicines | Series A | $130M | Feb 2026 |
| AAltesa Biosciences | Series B | $75M | Feb 2026 |
| AAltesa | Series B | $75M | Feb 2026 |
 Beacon Therapeutics | Series C | — | Jan 2026 |
 Memento Medicines | Series A | $93M | Jan 2026 |
| RQ Biotechnology | Series A | $115M | Jan 2026 |
| CcAMPfield | Series A | $180M | Jan 2026 |
| Coultreon Biopharma | Series A | $125M | Jan 2026 |
Top Co-Investors
Last updated: 20 October 2026